GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for ... there’s no longer a shortage of weight-loss drugs that had allowed for alternatives ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

While research suggests having a higher weight may increase your risk for certain conditions, people can be healthy at every ...

NEW YORK • Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the Food and Drug Administration clamps down on mass production ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

For every man who has cut carbs from his diet and dropped 10 pounds, there’s a woman who’s done exactly the same thing ...